60,000 Shares in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Purchased by Bank of Montreal Can

Bank of Montreal Can purchased a new stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 60,000 shares of the company’s stock, valued at approximately $446,000. Bank of Montreal Can owned approximately 0.58% of Avalo Therapeutics as of its most recent SEC filing.

Separately, Geode Capital Management LLC lifted its stake in Avalo Therapeutics by 937.0% in the fourth quarter. Geode Capital Management LLC now owns 104,853 shares of the company’s stock valued at $779,000 after acquiring an additional 94,742 shares during the last quarter. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on AVTX shares. HC Wainwright restated a “neutral” rating on shares of Avalo Therapeutics in a research note on Thursday, March 20th. Wedbush reaffirmed an “outperform” rating and issued a $18.00 price objective on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Piper Sandler initiated coverage on Avalo Therapeutics in a report on Friday, February 28th. They set an “overweight” rating and a $48.00 target price on the stock. Stifel Nicolaus assumed coverage on Avalo Therapeutics in a report on Tuesday, March 25th. They set a “buy” rating and a $36.00 price target for the company. Finally, Jefferies Financial Group began coverage on shares of Avalo Therapeutics in a report on Tuesday, March 25th. They issued a “buy” rating and a $23.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.00.

Avalo Therapeutics Stock Performance

Shares of NASDAQ:AVTX opened at $4.41 on Tuesday. The firm has a 50 day moving average of $6.84 and a 200-day moving average of $8.66. Avalo Therapeutics, Inc. has a 12 month low of $4.15 and a 12 month high of $17.49.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.